


HPC BIOSCIENCES LIMITED Unaudited Financial Results for the half Year ended on 30th Sep 2015

(Amount in Lacs)

	Six months ended		Year Ended	
Particulars	30.09.2015 (Unaudited)	30.09.2014 (UnAudited)	31.03.2015 (Audited)	
1. Income From Operations		44 452 200 00	30,944,378.00	
(a) Net Sales/Income from operations	13,826,445.00	14,462,388.00	1.691.950.00	
(b) Other Operating income	798,398.00	595,191.00		
Total Income from Operations (1)	14,624,843.00	15,057,579.00	32,636,328.00	
2. Expenditure			1 527 440 00	
(a) Increase / decrease in stock in trade and WIP	(410,250.00)	672,740.00	1,527,440.00	
(b) Consumption of Raw Material	-	*		
(c) Purchase of Trade Goods		-	2,425,000.00	
(e) Employees Cost	1,433,840.00	881,266.00	2,530,329.00	
(f) Depreciation and Amortization Expenses	6,936,337.51	6,810,624.38	14,117,147.23	
(g) Finance Cost	-	-		
(f) Other Expenses	2,514,294.00	2,024,061.00	4,469,289.60	
Total Expenses (2)	10,474,221.51	10,388,691.38	25,069,205.83	
Profit from Operations before other income, interest and Exceptional Item (1	4,150,621.49	4,668,887.62	7,567,122.17	
4. Other Income	-	-		
5. Profit before Interest & Exceptional Item (3+4)	4,150,621.49	4,668,887.62	7,567,122.17	
6. Interest	-		2 5 5 7 4 7 7 4 7	
7. Profit after Interest but befor Exceptional Item (5-6)	4,150,621.49	4,668,887.62	7,567,122.17	
8. Exceptional Items		. 440 007 57	255242242	
9. Profit (+)/ Loss (-) from ordinary activities before tax (7+8)	4,150,621.49	4,668,887.62	7,567,122.17	
10.Tax expenses			£33.043.0V	
- Current Tax	246,704.98	183,914.02	522,813.00	
- Deferred Tax Liabilities / (Assets)			16 354 00	
- Income Tax Adjustments		0. 072 50	(6,254.00	
11. net profit (+)/Loss(-) from ordinary Activities after tax (9-10)	3,903,916.51	4,484,973.60	7,050,563.17	
12. Extraordinary Item (net of tax expenses Rs.)			200000000	
13. Net Profit (+)/Loss(-) for the period (11-12)	3,903,916.51	4,484,973.60	7,050,563.1	
14. Paid-up equity share capital (face value of share of 10/-)	159,600,000.00	159,600,000.00	159,600,000.00	
- equity share (face value of share of 10/-)	700 000 000	15,960,000	450 500 00	
- equity share (face value of share of 1/-)	159,600,000	-	159,600,00	
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year				
16. Earnings Per Share (EPS)				
(a) Basic and diluted EPS before Extraordinary items for the period, for the year				
to date and for the previous year (not to be annualized)	0.02	0.28	0.0	
(b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	0.02	0.28	0.0	



Email id: hpcbiosci@yahoo.com : website: www.hpcbiosciences.com

PART II			
A PARTICULARS OF SHAREHOLDINGS			
1 Public Shareholding			
- Number of shares	124,610,000	124,610,000	124,610,000
- Percentage of shareholding	78.08	78.08	78.08
2 Promoters and Promoter Group Shareholding			
a) Pledged / Encumbered			
- Number of Shares			
Percentage of shares (as a % of the total — Shareholding of promoter and promoter and promoter group)			
- Percentage of shares (as a % of the total share capital of the issuer)			
b) Non – encumbered			
- Number of shares	34,990,000	34,990,000	34,990,000
 Percentage of shares (as a % of the total shareholding of the Promoter and promoter group) 	100.00	100.00	100.00
Percentage of shares (as a % of the total share capital of the issuer)	21.92	21.92	21.92

Date: 14.11.2015 Place: Delhi

1. STATEMENT OF ASSETS AND LIABILITIES AS AT 30.09.2015

(Amount in Lacs)

Sr. No.	Particulars	30.09.2015	31.03.2015
		Unaudited	Audited
L	EQUITY AND LIABILITIES	2.50	
1)	Shareholder's funds		
(a)	Share Capital	159,600,000.00	159,600,000.00
(b)	Reserves and Surplus	140,555,078.03	136,651,161.07
(c)	Money Received against.Share Warrants		
2)	Share Application Money (Pending Allotment)	100	-
3)	Non-Current liabilities		
(a)	Long term Borrowings	-	180
(b)	Deffered tax liabilities (net)	141	
(c)	Other long Term Liabilities		
(d)	Long Term Provisions		180
4)	Current Liabilities	200	
(a)	Short Term Borrowings	3.5	150
(b)	Trade Payables		
(c)	Other Current Liabilities	692,672.00	485,366.00
(d)	Short- Term Provisions	769,517.53	301,362.00
	Total Equity & Liabilities	301,617,267.56	297,037,889.07
II.	ASSETS		
1)	Non- Current Assets		
(a)	Fixed Assets	74,290,648.66	81,226,986.17
(b)	Non-current investments	3,000,000.00	3,000,000.00
(c)	Defered tax assets (net)		-
(d)	Long term loans and advances	36,875,000.00	36,875,000.00
(e)	Other non-current assets	2,670,916.00	3,267,114.00
2)	Current Assets		
(a)	Inventories	7,094,590.00	6,684,340.00
(b)	Trade receivables	32,630,445.00	19,804,000.00
(c)	Cash and cash equivalents	6,390,541.00	8,643,239.90
(d)	Short term loans and advances	138,373,433.90	137,534,126.0
(e)	Other current assets	291,693.00	3,083.00
	Total Assets	301,617,267.56	297,037,889.0


- 2 The above results have been reviewed by the Audit Committee & recommended for the Approval of the Board. Board approved the same in its meeting held on 14.11.2015.
- The Figures are subject to the Limited Review Report.

 Previous period's figures have been regrouped / rearranged wherever necessary.

5

Particulars	30.09.2015
INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	Nii
Remaining unresolved at the end of the quarter	Nil

Place: New Delhi Dated: 14.11.2015



AUDITORS LIMITED REVIEW REPORT OF M/S HPC BIOSCIENCES LIMITED FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2015

TO,
THE BOARD OF DIRECTORS,
M/S HPC BIOSCIENCES LIMITED

- We have reviewed the accompanying statement of unaudited financial results of M/S HPC BIOSCIENCES LIMITED for the half year ended 30th September, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us.. This statement is the responsibility of the Company's Management, and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
- We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- Based on our review conducted as above, and read with the notes given in the accompanying financial statements of un-audited financial results, nothing has come to our attention that causes us to believe that the accompanying statement of un Audited Financial Results prepared in accordance with not disclosed the information required to be disclosed in terms of Clause 43 of the Listing Agreement(s) including the manner in which it is to be disclosed, or that it contains any material misstatement.

M/s. Singh R K & Associates Chartered Accountants

CA Rakesh Kumar Singh

FRN: 027247N M. No. 532096